Acrivon Therapeutics, Inc. (ACRV) — Stock Score Summary

Acrivon Therapeutics, Inc. (ACRV) has a MoatMap StockRank of 14/100 based on Quality (35/100), Value (42/100), and Momentum (21/100) factor scores. The current signal is STRONG SELL. Acrivon Therapeutics is a micro-cap clinical-stage oncology company. It lacks commercial revenues, has a high cash burn rate, and does not align with our focus on high-ROIC, established compounders.

Acrivon Therapeutics, Inc. is a clinical-stage biopharmaceutical company utilizing its proprietary Acrivon Predictive Precision Medicine (APPM) platform to develop targeted oncology therapeutics. The platform enables the identification of patient-specific protein biomarkers to predict drug response, matching the right patient with the right therapy. Acrivon's competitive moat is defined by this precision medicine approach, which aims to significantly increase clinical trial success rates for its pipeline candidates.

Key Financial Metrics

Price$1.42
Market Cap$70M
P/E (Forward)-0.79
Price/Book0.63
Return on Equity-60.4%
Return on Invested Capital-73.7%
Debt/Equity2.53
Gross Margin0.0%
Operating Margin0.0%
Free Cash Flow$-39M

Acrivon Therapeutics, Inc. operates in the Biotechnology industry, part of the Healthcare sector (United States).

Frequently Asked Questions

What is Acrivon Therapeutics, Inc.’s (ACRV) StockRank?
MoatMap’s StockRank for Acrivon Therapeutics, Inc. (ACRV) is 14/100, with a Strong Sell signal. It is a composite of Quality (35), Value (42), and Momentum (21) factor ranks across MoatMap’s 19,000+ stock universe.
Does Acrivon Therapeutics, Inc. have an economic moat?
Acrivon Therapeutics, Inc. (ACRV) has a Quality factor score of 35/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Acrivon Therapeutics, Inc. a buy, hold, or sell?
MoatMap’s current signal for Acrivon Therapeutics, Inc. (ACRV) is Strong Sell, based on a StockRank of 14/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is Acrivon Therapeutics, Inc. in?
Acrivon Therapeutics, Inc. (ACRV) operates in the Healthcare sector, specifically the Biotechnology industry (United States).
Browse all ranked stocksACRV deep dive reportAI ChampionsHow we score stocksSense-check another stock